IMTX
Immatics N.V.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 17 ▲ Immatics announced a deep and durable remission in a pediatric patie…
- May 31 ▲ Immatics presented extended Phase 1 data for its TCR bispecific IMA4…
- Jun 1 ▲ Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1…
- Jun 1 ▲ Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-ce…
- Aug 18 Immatics reported Q2 2026 financial results showing a net loss of €6…
- Aug 18 Immatics reported Q2 2026 earnings with a narrower-than-expected net…
- Aug 26 ▲ 1 insider buy $7.5M at $8.69
- Aug 26 ▼ Immatics N.V. completed a public offering of 15,535,100 ordinary sha…
- Aug 27 ▲ Director Perceptive Advisors LLC purchased 863,060 shares of Immatic…
- Oct 14 Stifel initiates
- Oct 23 ▲ Immatics N.V. released updated Phase 1 data for its IMA203CD8 PRAME-…
- Oct 24 ▲ Immatics presented updated Phase 1b data for IMA402 PRAME bispecific…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $7.5M at an average $8.69. No open-market sales. Price is 29% below their cost.
- InstitutionsBULLISH
Q3 2026: 13 added (0 new), 4 trimmed or exited.
- AnalystsBULLISH
16 of 17 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.497 → −$0.496 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −2.1% to 3.67M shares. 3.0 days to cover, ≈2.5% of shares.
- TrendDOWNTREND
19% below its 50-day average. New closing low $6.17 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Aberdeen Group plc | ADD | $10.8M |
| Qube Research & Technologies Ltd | ADD | $8.7M |
| JANE STREET GROUP, LLC | DOUBLED | $3.5M |
| HRT FINANCIAL LP | DOUBLED | $2.3M |
| ALPS ADVISORS INC | ADD | $1.7M |
| BlackRock, Inc. | DOUBLED | $1.0M |
| Jump Financial, LLC | TRIM | $632.4K |
| CITIGROUP INC | TRIM | $409.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +143%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 14, 2026 | Stifel INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
PERCEPTIVE ADVISORS LLC Director Aug 26, 2026 | BUY | $7.5M |
Pepin James Nelson Gen Counsel and Corp Secretary Aug 14, 2026 | AWARD | 181,200 sh |
Pepin James Nelson Gen Counsel and Corp Secretary Aug 14, 2026 | AWARD | 43,800 sh |
Chambre Peter Alan Director Jun 16, 2026 | AWARD | 48,000 sh |
Forster Eliot Director Jun 16, 2026 | AWARD | 48,000 sh |
Carter Paul Rutherford Director Jun 16, 2026 | AWARD | 48,000 sh |
ATIEH MICHAEL G Director Jun 16, 2026 | AWARD | 48,000 sh |
Hothum Mathias Director Jun 16, 2026 | AWARD | 48,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.50 | -$0.54–-$0.42 | +1.5% | $9.1M |
| Next Q | -$0.59 | -$0.67–-$0.52 | -0.3% | $5.5M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | -$1.98 | -$2.27–-$1.63 | +2.2% | $31.4M |
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 7 press releases · 6 bullish · 2 bearish · 2 mixed · 6 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Investment Management, Inc. filed an amendment to its Schedule 13G, reporting beneficial ownership of 25,149,155 common shares (17.1%) of Immatics N.V. as of September 30, 2026. This is a routine passive stake update with no indication of activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 13, 2026
Montanova Capital, LLC filed Amendment No. 4 to its Schedule 13G, reporting beneficial ownership…
Monitor for any future conversion to Schedule 13D, which would signal an activist intent. The passive stake remains unchanged, so no immediate trading catalyst.
- NEUTRAL 6-KNov 10, 2026
Immatics reported Q3 2026 collaboration revenue of EUR 6.9M (up 33% YoY) and a net loss of EUR…
The key catalyst is SUPRAME Phase 3 topline data in H1 2027. Monitor enrollment completion by year-end 2026 and any updates on the BLA submission timeline. The activist stake by Perceptive Advisors…
- NEUTRAL PRESS-RELEASENov 10, 2026
Immatics reported Q3 2026 net loss of $86.3M (€76.0M), wider than the $57.3M loss a year ago…
SUPRAME enrollment completion by year-end and H1 2027 PFS data are the key catalysts. Cash runway into Q4 2028 reduces near-term financing risk. Monitor BLA submission timing in 2027.
All IMTX filing & press-release reports (23)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- 6-K reportNov 10, 2026
- PRESS-RELEASE reportNov 10, 2026
- 6-K reportOct 26, 2026
- PRESS-RELEASE reportOct 24, 2026
- 6-K reportOct 23, 2026
- INSIDER-BUY reportAug 27, 2026
- 6-K reportAug 26, 2026
- 6-K reportAug 18, 2026
- PRESS-RELEASE reportAug 18, 2026
- 6-K reportJun 2, 2026
- 6-K reportJun 1, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportMay 30, 2026
- 6-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 6-K reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026
- 6-K reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 5, 2026